VTAK terminates its ATM equity offering, secures $36.5 million from institutional investors to strengthen its balance sheet and support growth.
Quiver AI Summary
Catheter Precision, Inc. (NYSE American: VTAK) announced the termination of its at-the-market (ATM) equity offering program and the completion of a strategic financing transaction with institutional investors worth up to $36.5 million aimed at fostering growth. This move strengthens the company's balance sheet and enhances its liquidity, aligning institutional capital for long-term value creation. The company's short-term notes will be converted to long-term by extending maturities, and around $9 million in liabilities will also be converted into equity. CEO David Jenkins emphasized that this restructuring solidifies financial stability and allows Catheter Precision to pursue growth initiatives more effectively, reinforcing investor confidence in the company's strategy.
Potential Positives
- Termination of the ATM equity offering program simplifies capital structure and eliminates financial burdens from legacy financing.
- Secured up to $36.5 million in strategic institutional capital to support accelerated growth and expansion initiatives.
- Strengthening of the balance sheet and liquidity through the conversion of short-term notes to long-term liabilities enhances financial stability.
- Alignment with long-term institutional partners increases investor confidence in the company's growth strategy.
Potential Negatives
- Termination of the ATM equity offering program may indicate a lack of confidence in securing funds through this method, potentially signaling liquidity issues.
- Converting short-term notes to long-term liabilities might imply that the company is experiencing cash flow concerns, as they are postponing immediate financial obligations.
- Accumulation of $9 million in additional short and long-term liabilities suggests increasing debt levels, which could raise concerns among investors about financial stability.
FAQ
What is the recent announcement from Catheter Precision (VTAK)?
Catheter Precision has announced the termination of its ATM equity offering program and secured up to $36.5 million from institutional investors.
How will the funding support Catheter Precision's growth?
The funding will enhance financial flexibility, allowing the company to advance key growth initiatives and expand its market presence.
What changes occurred in the company's financial structure?
The company converted short-term notes to long-term debt, strengthening its balance sheet and liquidity.
Who commented on the company's strategic financing?
David Jenkins, CEO and Chairman of VTAK, emphasized the positive impact of the financing on the company's financial position.
Is this press release an offer to buy securities?
No, this press release does not constitute an offer to sell or solicit an offer to buy any securities.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program
Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation
FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market (“ATM”) equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth.
Key Highlights:
- ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated.
- Strategic institutional capital secured to fund expansion
- Balance sheet and liquidity significantly strengthened
- The company’s short-term notes have been converted to long term by extending maturities out to two and three years
-
Additional short and long-term liabilities of approximately $9 million on the 9/30/25 balance sheet are being converted into equity
Executive Commentary
“This financing and balance sheet restructuring strengthens our financial position and also reinforces institutional investor confidence in our strategy,” said David Jenkins, CEO and Chairman of VTAK.
Jenkins added, “By eliminating legacy financing overhang and aligning ourselves with long-term institutional partners, we’ve enhanced our ability to execute with speed, discipline, and focus.”
Jenkins concluded, “We now move forward from a position of financial strength, supported by capital, stability, and strategic alignment to drive meaningful shareholder value through disciplined growth.”
Capital Strategy Update
This strategic institutional investment provides the Company with financial flexibility to:
- Advance key growth initiatives
- Scale multiple business opportunities
-
Expand market presence and execution capabilities
Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026, and February 12th for additional details regarding the transaction.
About Catheter Precision
Catheter Precision
is a U.S.-based medical device company developing innovative solutions to improve the treatment of cardiac arrhythmias. The Company is committed to bringing new technologies to market through physician collaboration and continued product innovation.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company’s SEC filings, available at
www.sec.gov
. The Company undertakes no obligation to update these statements except as required by law.
CONTACTS:
Investor Relations
973-691-2000
[email protected]
# # #
